Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization

Journal of Ocular Pharmacology and Therapeutics

Volumn 15, Issue 5, 1999, Pages 425-428

  Martidis, Adam ^a   Miller, David G ^a   Ciulla, Thomas A ^a   Danis, Ronald P ^a   Moorthy, Ramana S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISONE; TRIAMCINOLONE;

ADULT; ANXIETY; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MALE; OCULAR HISTOPLASMOSIS; ORAL DRUG ADMINISTRATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; WEIGHT GAIN;

EID: 0032837253     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1999.15.425     Document Type: Article

References (5)

1. Schlaegel, T.F. Corticosteroids in the treatment of ocular histoplasmosis. Int. Ophthalmol. Clin. 15:111-123, 1975.
2. Danis, R.P., Bingaman, D.P., Yang, Y., and Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 103(12):2099-2104, 1996.
3. Kleiner, R.C., Ratner, C.M., Enger, C., and Fine, S.L. Subfoveal neovascularization in the ocular histoplasmosis syndrome. Retina 8:225-229, 1988.
4. Olk, R.J., Burgess, D.B., and McCormick, P.A. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome: visual prognosis. Ophthalmology 91:1592-1602, 1984.
5. Penfold, P.L., Gyory, J.F., Hunyor, A.B., and Billson, F.A. Exudative macular degeneration and intravitreal triamcinolone, a pilot study. Austrl. NZ J. Ophthalmol. 23(4):293-296, 1995.